Vyndamax
PreclinicalSmall molecule
PfizerVyndamax is one of 6 small molecule programs targeting Transthyretin Amyloid Cardiomyopathy. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Transthyretin Amyloid Cardiomyopathy
#DrugCompanyPhaseTrials
1Onpattro
Alnylam PharmaceuticalsApproved
Vyndaqel
KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Approved
Jardiance
Boehringer IngelheimApproved
Attruby
NNavire Pharma Inc., a BridgeBio company
Approved
Wainua (autoinjector)
AstraZenecaPhase 3
Vyndamax
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Vyndamax. EMBL-EBI & Wellcome Sanger Institute.
- [4]